Wondering about the most recent progress in Myasthenia Gravis treatments research and clinical trials?
Wondering about the most recent progress in myasthenia gravis treatments research and clinical trials?
Join a “What’s New in MG Research” webinar to learn about the latest research results, key clinical trial phases, and current outcomes from top research trials taking place right now.
Up Next:
argenx Clinical Trial Update – Adapt Seron
Thursday, June 20 3:00 PM EST / 12:00 PM PDT
Presented by: Jeffrey T. Guptill, MD, MA, MHS
Register
Session Description: Adapt seron is a phase 3 study to evaluate the efficacy of safety of Efgartigimod IV in patients with AChr – gMG, including MuSK-Ab, LRP4-Ab, and gMG patients with no identifiable autoantibodies.
About the Presenter: Dr. Jeffrey Guptill is Neuromuscular Franchise Lead in Clinical Development at argenx. In this role he oversees the late-stage clinical development programs for efgartigimod (FcRn inhibitor) and empasibrupart (C2 complement inhibitor). He is also Adjunct Associate Professor of Neurology at Duke University School of Medicine. Dr. Guptill received his medical training at Virginia Commonwealth University and subsequently completed an adult neurology residency and neuromuscular medicine/EMG and advanced neuromuscular disease fellowships at Duke University. Prior to joining argenx, he was a tenured Associate Professor of Neurology at Duke University.